CoChat

Bone marrow mononuclear cell therapy for patients with cirrhosis: a Phase 1 study: Bone marrow cells in cirrhosis

Couto, Bianca G., Goldenberg, Regina C. dos Santos, da Fonseca, Léa M. B., Thomas, James, Gutfilen, Bianca, Resende, Célia M. C., Azevedo, Feliciano, Mercante, Daniel R., Torres, André L. Moreira, Coelho, Henrique S. M., Maiolino, Angelo, Alves, Alessandra L. dos Anjos, Dias, Juliana V., Moreira, Maria C. R., Sampaio, Ana L. S. B., Sousa, Maria A. J., Kasai-Brunswick, Tais H., Souza, Sérgio A. L., Campos-de-Carvalho, Antonio C., Rezende, Guilherme F. da Motta · 2011 · Liver International
Cited by 67

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Bone marrow-derived cell therapy has been investigated in patients with severe liver disease. AIMS: To assess the feasibility, safety and cell kinetics of autologous bone marrow-derived mononuclear cells (BMMCs) infusion in cirrhotic patients. METHODS: BMMCs were isolated from autologous bone marrow and 10% of the cells were labelled with (99m)Tc-SnCl₂. Whole body scintigraphy (WBS) was performed 3 and 24 h after infusion via the hepatic artery. Liver function and image were followed during 1 year. RESULTS: Eight patients received 2.0-15.0 × 10⁸ cells. Three and 24-h WBS showed mean hepatic radiotracer retentions of 41 and 32% respectively. One case of dissection of the hepatic artery and one case of Tako-tsubo syndrome occurred as early complications. A patient developed a cutaneous immunomediated disorder and another patient developed hepatocellular carcinoma (HCC) 12 months after infusion. A reduction in bilirubin was shown at 1 week while serum albumin increased above baseline up to 1 month after infusion (P<0.05). CONCLUSIONS: BMMCs infusion is feasible and practical in a clinical setting. In vivo tracking of labelled cells demonstrated that the hepatic artery route successfully delivered BMMCs to the liver. The early improvement of laboratory indices of liver function should be interpreted with caution, because this study was not designed to evaluate efficacy. The median Model for End-Stage Liver Disease score had not deteriorated 1 year later. The occurrence of a graft-versus-host disease-like phenomenon highlights the importance of sustained vigilance even when giving autologous cells. Controlled studies are needed to determine whether BMMCs infusion affects HCC development in cirrhosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1478-3231.2010.02424.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 67

Metadata

Authors
Couto, B. G., Goldenberg, R. C. D. S., da Fonseca, L. M. B., Thomas, J., Gutfilen, B., Resende, C. M. C., Azevedo, F., Mercante, D. R., Torres, A. L. M., Coelho, H. S. M., Maiolino, A., Alves, A. L. D. A., Dias, J. V., Moreira, M. C. R., Sampaio, A. L. S. B., Sousa, M. A. J., Kasai-Brunswick, T. H., Souza, S. A. L., Campos-de-Carvalho, A. C., & Rezende, G. F. D. M.
Venue
Liver International
Publisher
Wiley
Published
2011-01-19
Volume
31
Issue
3
Pages
391-400
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
OpenAlex
W2157300041
Cited by
67
References
4
FWCI
4.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bone marrow mononuclear cell therapy for patients with cirrhosis: a Phase 1 study: Bone marrow cells in cirrhosis. https://app.cochat.ai/papers/10.1111/j.1478-3231.2010.02424.x
The paper
Couto, B. G., Goldenberg, R. C. D. S., da Fonseca, L. M. B., Thomas, J., Gutfilen, B., Resende, C. M. C., Azevedo, F., Mercante, D. R., Torres, A. L. M., Coelho, H. S. M., Maiolino, A., Alves, A. L. D. A., Dias, J. V., Moreira, M. C. R., Sampaio, A. L. S. B., Sousa, M. A. J., Kasai-Brunswick, T. H., Souza, S. A. L., Campos-de-Carvalho, A. C., & Rezende, G. F. D. M. (2011). Bone marrow mononuclear cell therapy for patients with cirrhosis: a Phase 1 study: Bone marrow cells in cirrhosis. Liver International. https://doi.org/10.1111/j.1478-3231.2010.02424.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.